Applied DNA to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Applied DNA Sciences (NASDAQ: APDN) announced that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The virtual presentation will be available on September 13, 2021, at 7:00 am (EST) via the Company's website. Applied DNA is known for its LinearDNA platform, which aids in large-scale DNA production for various applications, including diagnostics and drug development. The company also offers safeCircle, a pooled COVID-19 testing program.

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23^rd Annual Global Investment Conference to be held virtually from September 13 – 15, 2021.

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on September 13, 2021, and can be accessed through the Investors Relations section of Applied DNA website at www.adnas.com or directly through the webcast link. An archived replay of the webcast will be available on the Company’s website after the conference.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA^™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle^™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea^™ COVID-19 Assay Kit. safeCircle is designed to look for infection within defined populations or communities utilizing pooled testing methodologies that increase testing efficiencies. The Company has also developed and plans to seek EUA-authorization for its Linea^™ SARS-CoV-2 Mutation Panel, an assay-based panel for the detection of certain SARS-CoV-2 genetic mutations.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’

Applied DNA is a member of the Russell Microcap^® Index.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005270/en/

For Applied DNA:

Investor: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: www.adnas.com

Twitter: @APDN

Source: Applied DNA Sciences, Inc.

FAQ

When will Applied DNA Sciences present at the H.C. Wainwright Global Investment Conference?

Applied DNA Sciences will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time is Applied DNA's presentation scheduled for?

The presentation by Applied DNA Sciences is scheduled for 7:00 am (EST) on September 13, 2021.

Where can I watch the Applied DNA presentation?

The presentation can be accessed via the Investor Relations section of Applied DNA's website.

What is the focus of Applied DNA Sciences' LinearDNA platform?

The LinearDNA platform is designed for large-scale DNA production for in vitro diagnostics and nucleic acid-based drug development.

What is the purpose of Applied DNA's safeCircle program?

The safeCircle program is a pooled COVID-19 testing initiative aimed at identifying infections within populations.